AbbVie – Capital Expenditure

Quarterly charts & data from official filings

Timeframe

Capital expenditure

Capital expenditureTable view

Earnings release date
Capital expenditure
Earnings release date:29 Apr. 26
Capital expenditure:
265,000,000 $-19.5%
Earnings release date:04 Feb. 26
Capital expenditure:
329,000,000 $-13.6%
Earnings release date:31 Oct. 25
Capital expenditure:
381,000,000 $+41.6%
Earnings release date:31 Jul. 25
Capital expenditure:
269,000,000 $+14.5%
Earnings release date:25 Apr. 25
Capital expenditure:
235,000,000 $-19.2%
Earnings release date:31 Jan. 25
Capital expenditure:
291,000,000 $+16.9%
Earnings release date:30 Oct. 24
Capital expenditure:
249,000,000 $+3.3%
Earnings release date:25 Jul. 24
Capital expenditure:
241,000,000 $+24.9%
Earnings release date:26 Apr. 24
Capital expenditure:
193,000,000 $-5.9%
Earnings release date:02 Feb. 24
Capital expenditure:
205,000,000 $-6.4%
Earnings release date:27 Oct. 23
Capital expenditure:
219,000,000 $+23.0%
Earnings release date:27 Jul. 23
Capital expenditure:
178,000,000 $+1.7%
Earnings release date:27 Apr. 23
Capital expenditure:
175,000,000 $-17.8%
Earnings release date:09 Feb. 23
Capital expenditure:
213,000,000 $+20.3%
Earnings release date:28 Oct. 22
Capital expenditure:
177,000,000 $+23.8%
Earnings release date:29 Jul. 22
Capital expenditure:
143,000,000 $-11.7%
Earnings release date:29 Apr. 22
Capital expenditure:
162,000,000 $

Revenue by segment

Revenue by segmentTable view

Earnings release date
Immunology
Neuroscience
Oncology
Aesthetics
Eye Care
Other Key Products
Other
Total
Earnings release date:29 Apr. 26
Immunology:
7,290,000,000 $-15.5%
Neuroscience:
2,875,000,000 $-2.9%
Oncology:
1,631,000,000 $-2.0%
Aesthetics:
1,186,000,000 $-7.8%
Eye Care:
–
Other Key Products:
995,000,000 $+12.6%
Other:
1,025,000,000 $+66.1%
Total:
15,002,000,000 $-9.7%
Earnings release date:04 Feb. 26
Immunology:
8,626,000,000 $+9.4%
Neuroscience:
2,961,000,000 $+4.2%
Oncology:
1,664,000,000 $-1.1%
Aesthetics:
1,286,000,000 $+7.8%
Eye Care:
580,000,000 $+13.9%
Other Key Products:
884,000,000 $-12.1%
Other:
617,000,000 $-6.5%
Total:
16,618,000,000 $+5.3%
Earnings release date:31 Oct. 25
Immunology:
7,885,000,000 $+3.3%
Neuroscience:
2,841,000,000 $+5.9%
Oncology:
1,682,000,000 $+0.4%
Aesthetics:
1,193,000,000 $-6.7%
Eye Care:
509,000,000 $-1.0%
Other Key Products:
1,006,000,000 $-3.0%
Other:
660,000,000 $+9.5%
Total:
15,776,000,000 $+2.3%
Earnings release date:31 Jul. 25
Immunology:
7,631,000,000 $+21.8%
Neuroscience:
2,683,000,000 $+17.6%
Oncology:
1,676,000,000 $+2.6%
Aesthetics:
1,279,000,000 $+16.1%
Eye Care:
514,000,000 $+1.6%
Other Key Products:
1,037,000,000 $+28.2%
Other:
603,000,000 $-19.3%
Total:
15,423,000,000 $+15.6%
Earnings release date:25 Apr. 25
Immunology:
6,264,000,000 $-14.1%
Neuroscience:
2,282,000,000 $-9.0%
Oncology:
1,633,000,000 $-3.4%
Aesthetics:
1,102,000,000 $-15.1%
Eye Care:
506,000,000 $-21.7%
Other Key Products:
809,000,000 $-11.3%
Other:
747,000,000 $-0.7%
Total:
13,343,000,000 $-11.6%
Earnings release date:31 Jan. 25
Immunology:
7,294,000,000 $+3.5%
Neuroscience:
2,509,000,000 $+6.2%
Oncology:
1,691,000,000 $+0.2%
Aesthetics:
1,298,000,000 $+4.8%
Eye Care:
646,000,000 $+23.0%
Other Key Products:
912,000,000 $+4.3%
Other:
752,000,000 $+3.6%
Total:
15,102,000,000 $+4.4%
Earnings release date:30 Oct. 24
Immunology:
7,046,000,000 $+1.1%
Neuroscience:
2,363,000,000 $+9.3%
Oncology:
1,687,000,000 $+3.2%
Aesthetics:
1,239,000,000 $-10.9%
Eye Care:
525,000,000 $-1.5%
Other Key Products:
874,000,000 $-9.1%
Other:
726,000,000 $-10.4%
Total:
14,460,000,000 $+0.0%
Earnings release date:25 Jul. 24
Immunology:
6,971,000,000 $+29.8%
Neuroscience:
2,162,000,000 $+10.0%
Oncology:
1,634,000,000 $+5.9%
Aesthetics:
1,390,000,000 $+11.3%
Eye Care:
533,000,000 $-0.9%
Other Key Products:
962,000,000 $+6.9%
Other:
810,000,000 $+8.9%
Total:
14,462,000,000 $+17.5%
Earnings release date:26 Apr. 24
Immunology:
5,371,000,000 $-22.8%
Neuroscience:
1,965,000,000 $-6.2%
Oncology:
1,543,000,000 $+2.3%
Aesthetics:
1,249,000,000 $-8.9%
Eye Care:
538,000,000 $-8.0%
Other Key Products:
900,000,000 $-7.0%
Other:
744,000,000 $-9.4%
Total:
12,310,000,000 $-13.9%
Earnings release date:02 Feb. 24
Immunology:
6,953,000,000 $+2.5%
Neuroscience:
2,094,000,000 $+2.5%
Oncology:
1,509,000,000 $-0.2%
Aesthetics:
1,371,000,000 $+10.7%
Eye Care:
585,000,000 $-3.3%
Other Key Products:
968,000,000 $+0.5%
Other:
821,000,000 $+5.0%
Total:
14,301,000,000 $+2.7%
Earnings release date:27 Oct. 23
Immunology:
6,783,000,000 $-0.4%
Neuroscience:
2,043,000,000 $+8.4%
Oncology:
1,512,000,000 $+2.3%
Aesthetics:
1,239,000,000 $-10.5%
Eye Care:
605,000,000 $-1.9%
Other Key Products:
963,000,000 $+1.7%
Other:
782,000,000 $+5.5%
Total:
13,927,000,000 $+0.4%
Earnings release date:27 Jul. 23
Immunology:
6,813,000,000 $+21.9%
Neuroscience:
1,885,000,000 $+11.2%
Oncology:
1,478,000,000 $+4.4%
Aesthetics:
1,384,000,000 $+6.5%
Eye Care:
617,000,000 $+1.5%
Other Key Products:
947,000,000 $+2.0%
Other:
741,000,000 $+7.2%
Total:
13,865,000,000 $+13.4%
Earnings release date:27 Apr. 23
Immunology:
5,587,000,000 $-29.5%
Neuroscience:
1,695,000,000 $-0.9%
Oncology:
1,416,000,000 $-13.2%
Aesthetics:
1,300,000,000 $+1.0%
Eye Care:
608,000,000 $+3.1%
Other Key Products:
928,000,000 $-5.9%
Other:
691,000,000 $-30.3%
Total:
12,225,000,000 $-19.2%
Earnings release date:09 Feb. 23
Immunology:
7,925,000,000 $+3.6%
Neuroscience:
1,710,000,000 $+2.3%
Oncology:
1,631,000,000 $-1.2%
Aesthetics:
1,287,000,000 $-1.1%
Eye Care:
590,000,000 $-5.3%
Other Key Products:
986,000,000 $-0.4%
Other:
992,000,000 $+7.2%
Total:
15,121,000,000 $+2.1%
Earnings release date:28 Oct. 22
Immunology:
7,651,000,000 $+6.2%
Neuroscience:
1,672,000,000 $+0.8%
Oncology:
1,650,000,000 $+0.0%
Aesthetics:
1,301,000,000 $-5.1%
Eye Care:
623,000,000 $-13.1%
Other Key Products:
990,000,000 $+2.0%
Other:
925,000,000 $-8.3%
Total:
14,812,000,000 $+1.6%
Earnings release date:29 Jul. 22
Immunology:
7,207,000,000 $+17.4%
Neuroscience:
1,658,000,000 $+11.4%
Oncology:
1,650,000,000 $+0.2%
Aesthetics:
1,371,000,000 $-0.2%
Eye Care:
717,000,000 $-7.0%
Other Key Products:
971,000,000 $+7.1%
Other:
1,009,000,000 $-16.7%
Total:
14,583,000,000 $+7.7%
Earnings release date:29 Apr. 22
Immunology:
6,141,000,000 $
Neuroscience:
1,488,000,000 $
Oncology:
1,646,000,000 $
Aesthetics:
1,374,000,000 $
Eye Care:
771,000,000 $
Other Key Products:
907,000,000 $
Other:
1,211,000,000 $
Total:
13,538,000,000 $

Revenue by geographic location

Revenue by geographic locationTable view

Earnings release date
United States
International
Total
Earnings release date:29 Apr. 26
United States:
10,969,000,000 $-14.3%
International:
4,033,000,000 $+5.5%
Total:
15,002,000,000 $-9.7%
Earnings release date:04 Feb. 26
United States:
12,794,000,000 $+6.0%
International:
3,824,000,000 $+3.1%
Total:
16,618,000,000 $+5.3%
Earnings release date:31 Oct. 25
United States:
12,068,000,000 $+2.6%
International:
3,708,000,000 $+1.3%
Total:
15,776,000,000 $+2.3%
Earnings release date:31 Jul. 25
United States:
11,762,000,000 $+17.9%
International:
3,661,000,000 $+8.8%
Total:
15,423,000,000 $+15.6%
Earnings release date:25 Apr. 25
United States:
9,979,000,000 $-15.0%
International:
3,364,000,000 $-0.1%
Total:
13,343,000,000 $-11.6%
Earnings release date:31 Jan. 25
United States:
11,734,000,000 $+5.3%
International:
3,368,000,000 $+1.7%
Total:
15,102,000,000 $+4.4%
Earnings release date:30 Oct. 24
United States:
11,148,000,000 $+0.4%
International:
3,312,000,000 $-1.3%
Total:
14,460,000,000 $+0.0%
Earnings release date:25 Jul. 24
United States:
11,106,000,000 $+22.8%
International:
3,356,000,000 $+2.7%
Total:
14,462,000,000 $+17.5%
Earnings release date:26 Apr. 24
United States:
9,041,000,000 $-18.6%
International:
3,269,000,000 $+2.4%
Total:
12,310,000,000 $-13.9%
Earnings release date:02 Feb. 24
United States:
11,110,000,000 $+2.4%
International:
3,191,000,000 $+3.8%
Total:
14,301,000,000 $+2.7%
Earnings release date:27 Oct. 23
United States:
10,852,000,000 $+1.2%
International:
3,075,000,000 $-2.2%
Total:
13,927,000,000 $+0.4%
Earnings release date:27 Jul. 23
United States:
10,720,000,000 $+16.5%
International:
3,145,000,000 $+4.0%
Total:
13,865,000,000 $+13.4%
Earnings release date:27 Apr. 23
United States:
9,201,000,000 $-24.5%
International:
3,024,000,000 $+3.2%
Total:
12,225,000,000 $-19.2%
Earnings release date:09 Feb. 23
United States:
12,192,000,000 $+3.6%
International:
2,929,000,000 $-3.9%
Total:
15,121,000,000 $+2.1%
Earnings release date:28 Oct. 22
United States:
11,763,000,000 $+3.1%
International:
3,049,000,000 $-3.9%
Total:
14,812,000,000 $+1.6%
Earnings release date:29 Jul. 22
United States:
11,410,000,000 $+10.3%
International:
3,173,000,000 $-0.5%
Total:
14,583,000,000 $+7.7%
Earnings release date:29 Apr. 22
United States:
10,348,000,000 $
International:
3,190,000,000 $
Total:
13,538,000,000 $

Operating expenses

Operating expensesTable view

Earnings release date
Cost of products sold
Selling, general and administrative
Research and development
Acquired IPR&D and milestones
Other operating expense (income), net
Total
Earnings release date:29 Apr. 26
Cost of products sold:
4,218,000,000 $-7.3%
Selling, general and administrative:
3,578,000,000 $-8.1%
Research and development:
2,472,000,000 $-4.1%
Acquired IPR&D and milestones:
744,000,000 $-41.2%
Other operating expense (income), net:
–
Total:
11,012,000,000 $-8.8%
Earnings release date:04 Feb. 26
Cost of products sold:
4,552,000,000 $-14.2%
Selling, general and administrative:
3,895,000,000 $+9.1%
Research and development:
2,579,000,000 $+11.2%
Acquired IPR&D and milestones:
1,265,000,000 $-52.8%
Other operating expense (income), net:
-217,000,000 $
Total:
12,074,000,000 $-13.0%
Earnings release date:31 Oct. 25
Cost of products sold:
5,304,000,000 $+22.0%
Selling, general and administrative:
3,569,000,000 $+9.7%
Research and development:
2,319,000,000 $+8.8%
Acquired IPR&D and milestones:
2,680,000,000 $+225.6%
Other operating expense (income), net:
–
Total:
13,872,000,000 $+31.8%
Earnings release date:31 Jul. 25
Cost of products sold:
4,346,000,000 $+8.6%
Selling, general and administrative:
3,253,000,000 $-1.2%
Research and development:
2,131,000,000 $+3.1%
Acquired IPR&D and milestones:
823,000,000 $+231.9%
Other operating expense (income), net:
-24,000,000 $
Total:
10,529,000,000 $+9.6%
Earnings release date:25 Apr. 25
Cost of products sold:
4,002,000,000 $-9.0%
Selling, general and administrative:
3,293,000,000 $-14.6%
Research and development:
2,067,000,000 $-69.5%
Acquired IPR&D and milestones:
248,000,000 $-84.2%
Other operating expense (income), net:
–
Total:
9,610,000,000 $-42.1%
Earnings release date:31 Jan. 25
Cost of products sold:
4,396,000,000 $+4.4%
Selling, general and administrative:
3,855,000,000 $-8.3%
Research and development:
6,774,000,000 $+218.0%
Acquired IPR&D and milestones:
1,574,000,000 $+1819.5%
Other operating expense (income), net:
-7,000,000 $
Total:
16,592,000,000 $+56.1%
Earnings release date:30 Oct. 24
Cost of products sold:
4,212,000,000 $+0.2%
Selling, general and administrative:
4,205,000,000 $+24.5%
Research and development:
2,130,000,000 $+9.3%
Acquired IPR&D and milestones:
82,000,000 $-91.2%
Other operating expense (income), net:
–
Total:
10,629,000,000 $+1.6%
Earnings release date:25 Jul. 24
Cost of products sold:
4,202,000,000 $+2.6%
Selling, general and administrative:
3,377,000,000 $+1.9%
Research and development:
1,948,000,000 $+0.5%
Acquired IPR&D and milestones:
937,000,000 $+471.3%
Other operating expense (income), net:
–
Total:
10,464,000,000 $+10.0%
Earnings release date:26 Apr. 24
Cost of products sold:
4,094,000,000 $-28.2%
Selling, general and administrative:
3,315,000,000 $+3.8%
Research and development:
1,939,000,000 $+0.6%
Acquired IPR&D and milestones:
164,000,000 $-41.8%
Other operating expense (income), net:
–
Total:
9,512,000,000 $-14.4%
Earnings release date:02 Feb. 24
Cost of products sold:
5,704,000,000 $-12.0%
Selling, general and administrative:
3,193,000,000 $-5.3%
Research and development:
1,927,000,000 $+11.8%
Acquired IPR&D and milestones:
282,000,000 $+327.3%
Other operating expense (income), net:
–
Total:
11,106,000,000 $-4.6%
Earnings release date:27 Oct. 23
Cost of products sold:
6,485,000,000 $+52.9%
Selling, general and administrative:
3,372,000,000 $+3.2%
Research and development:
1,723,000,000 $-0.6%
Acquired IPR&D and milestones:
66,000,000 $-76.4%
Other operating expense (income), net:
–
Total:
11,646,000,000 $+24.5%
Earnings release date:27 Jul. 23
Cost of products sold:
4,240,000,000 $+6.4%
Selling, general and administrative:
3,268,000,000 $+7.5%
Research and development:
1,733,000,000 $-24.4%
Acquired IPR&D and milestones:
280,000,000 $+86.7%
Other operating expense (income), net:
-169,000,000 $-1590.0%
Total:
9,352,000,000 $-1.1%
Earnings release date:27 Apr. 23
Cost of products sold:
3,986,000,000 $-4.4%
Selling, general and administrative:
3,039,000,000 $-11.1%
Research and development:
2,292,000,000 $+28.0%
Acquired IPR&D and milestones:
150,000,000 $-38.3%
Other operating expense (income), net:
-10,000,000 $-900.0%
Total:
9,457,000,000 $-1.7%
Earnings release date:09 Feb. 23
Cost of products sold:
4,170,000,000 $-17.0%
Selling, general and administrative:
3,417,000,000 $+3.4%
Research and development:
1,790,000,000 $+10.9%
Acquired IPR&D and milestones:
243,000,000 $+507.5%
Other operating expense (income), net:
-1,000,000 $-100.4%
Total:
9,619,000,000 $-5.8%
Earnings release date:28 Oct. 22
Cost of products sold:
5,022,000,000 $+20.4%
Selling, general and administrative:
3,304,000,000 $-39.0%
Research and development:
1,614,000,000 $+0.3%
Acquired IPR&D and milestones:
40,000,000 $-85.1%
Other operating expense (income), net:
229,000,000 $+233.1%
Total:
10,209,000,000 $-9.6%
Earnings release date:29 Jul. 22
Cost of products sold:
4,170,000,000 $+2.9%
Selling, general and administrative:
5,412,000,000 $+73.1%
Research and development:
1,609,000,000 $+7.5%
Acquired IPR&D and milestones:
269,000,000 $+85.5%
Other operating expense (income), net:
-172,000,000 $
Total:
11,288,000,000 $+28.0%
Earnings release date:29 Apr. 22
Cost of products sold:
4,052,000,000 $
Selling, general and administrative:
3,127,000,000 $
Research and development:
1,497,000,000 $
Acquired IPR&D and milestones:
145,000,000 $
Other operating expense (income), net:
–
Total:
8,821,000,000 $

Profitability

ProfitabilityTable view

Earnings release date
Net income (shareholders)
Free cash flow
Total
Earnings release date:29 Apr. 26
Net income (shareholders):
695,000,000 $-61.7%
Free cash flow:
3,564,000,000 $-27.1%
Total:
4,259,000,000 $-36.5%
Earnings release date:04 Feb. 26
Net income (shareholders):
1,816,000,000 $+876.3%
Free cash flow:
4,889,000,000 $-26.4%
Total:
6,705,000,000 $-1.8%
Earnings release date:31 Oct. 25
Net income (shareholders):
186,000,000 $-80.2%
Free cash flow:
6,643,000,000 $+36.0%
Total:
6,829,000,000 $+17.3%
Earnings release date:31 Jul. 25
Net income (shareholders):
938,000,000 $-27.1%
Free cash flow:
4,884,000,000 $+248.9%
Total:
5,822,000,000 $+116.8%
Earnings release date:25 Apr. 25
Net income (shareholders):
1,286,000,000 $+5945.5%
Free cash flow:
1,400,000,000 $-79.3%
Total:
2,686,000,000 $-60.1%
Earnings release date:31 Jan. 25
Net income (shareholders):
-22,000,000 $-101.4%
Free cash flow:
6,757,000,000 $+30.0%
Total:
6,735,000,000 $-0.4%
Earnings release date:30 Oct. 24
Net income (shareholders):
1,561,000,000 $+13.9%
Free cash flow:
5,198,000,000 $+156.1%
Total:
6,759,000,000 $+98.8%
Earnings release date:25 Jul. 24
Net income (shareholders):
1,370,000,000 $+0.1%
Free cash flow:
2,030,000,000 $-47.2%
Total:
3,400,000,000 $-34.8%
Earnings release date:26 Apr. 24
Net income (shareholders):
1,369,000,000 $+66.5%
Free cash flow:
3,847,000,000 $-15.4%
Total:
5,216,000,000 $-2.9%
Earnings release date:02 Feb. 24
Net income (shareholders):
822,000,000 $-53.8%
Free cash flow:
4,548,000,000 $-38.2%
Total:
5,370,000,000 $-41.2%
Earnings release date:27 Oct. 23
Net income (shareholders):
1,778,000,000 $-12.2%
Free cash flow:
7,355,000,000 $+19.8%
Total:
9,133,000,000 $+11.9%
Earnings release date:27 Jul. 23
Net income (shareholders):
2,024,000,000 $+746.9%
Free cash flow:
6,141,000,000 $+52.8%
Total:
8,165,000,000 $+91.8%
Earnings release date:27 Apr. 23
Net income (shareholders):
239,000,000 $-90.3%
Free cash flow:
4,018,000,000 $-44.3%
Total:
4,257,000,000 $-56.1%
Earnings release date:09 Feb. 23
Net income (shareholders):
2,473,000,000 $-37.4%
Free cash flow:
7,215,000,000 $-2.8%
Total:
9,688,000,000 $-14.8%
Earnings release date:28 Oct. 22
Net income (shareholders):
3,949,000,000 $+327.4%
Free cash flow:
7,425,000,000 $+52.7%
Total:
11,374,000,000 $+96.6%
Earnings release date:29 Jul. 22
Net income (shareholders):
924,000,000 $-79.4%
Free cash flow:
4,862,000,000 $+2.4%
Total:
5,786,000,000 $-37.4%
Earnings release date:29 Apr. 22
Net income (shareholders):
4,490,000,000 $
Free cash flow:
4,746,000,000 $
Total:
9,236,000,000 $

Profit margin in %

Profit margin in %Table view

Earnings release date
Profit margin (shareholders)
Profit margin (free cash flow)
Earnings release date:29 Apr. 26
Profit margin (shareholders):
4.63 %-6.3 pp
Profit margin (free cash flow):
23.76 %-5.7 pp
Earnings release date:04 Feb. 26
Profit margin (shareholders):
10.93 %+9.7 pp
Profit margin (free cash flow):
29.42 %-12.7 pp
Earnings release date:31 Oct. 25
Profit margin (shareholders):
1.18 %-4.9 pp
Profit margin (free cash flow):
42.11 %+10.4 pp
Earnings release date:31 Jul. 25
Profit margin (shareholders):
6.08 %-3.6 pp
Profit margin (free cash flow):
31.67 %+21.2 pp
Earnings release date:25 Apr. 25
Profit margin (shareholders):
9.64 %+9.8 pp
Profit margin (free cash flow):
10.49 %-34.3 pp
Earnings release date:31 Jan. 25
Profit margin (shareholders):
-0.15 %-10.9 pp
Profit margin (free cash flow):
44.74 %+8.8 pp
Earnings release date:30 Oct. 24
Profit margin (shareholders):
10.8 %+1.3 pp
Profit margin (free cash flow):
35.95 %+21.9 pp
Earnings release date:25 Jul. 24
Profit margin (shareholders):
9.47 %-1.6 pp
Profit margin (free cash flow):
14.04 %-17.2 pp
Earnings release date:26 Apr. 24
Profit margin (shareholders):
11.12 %+5.4 pp
Profit margin (free cash flow):
31.25 %-0.6 pp
Earnings release date:02 Feb. 24
Profit margin (shareholders):
5.75 %-7.0 pp
Profit margin (free cash flow):
31.8 %-21.0 pp
Earnings release date:27 Oct. 23
Profit margin (shareholders):
12.77 %-1.8 pp
Profit margin (free cash flow):
52.81 %+8.5 pp
Earnings release date:27 Jul. 23
Profit margin (shareholders):
14.6 %+12.6 pp
Profit margin (free cash flow):
44.29 %+11.4 pp
Earnings release date:27 Apr. 23
Profit margin (shareholders):
1.96 %-14.4 pp
Profit margin (free cash flow):
32.87 %-14.8 pp
Earnings release date:09 Feb. 23
Profit margin (shareholders):
16.35 %-10.3 pp
Profit margin (free cash flow):
47.72 %-2.4 pp
Earnings release date:28 Oct. 22
Profit margin (shareholders):
26.66 %+20.3 pp
Profit margin (free cash flow):
50.13 %+16.8 pp
Earnings release date:29 Jul. 22
Profit margin (shareholders):
6.34 %-26.8 pp
Profit margin (free cash flow):
33.34 %-1.7 pp
Earnings release date:29 Apr. 22
Profit margin (shareholders):
33.17 %
Profit margin (free cash flow):
35.06 %